Skip to main content

Releuko News

Updated FDA Labeling Recommendations for Biosimilar and Interchangeable Biosimilar Products

October 26, 2023 – Over the last eight years, FDA has approved more than 40 biosimilar products (biosimilars), and they have become an important treatment option for health care professionals and...

FDA Approves Releuko (filgrastim-ayow), a Biosimilar to Neupogen

PISCATAWAY, N.J.--(BUSINESS WIRE)-- March 2, 2022 Kashiv Biosciences, LLC (“Kashiv”) today announced the U.S. Food and Drug Administration (FDA) approval of its Biologics License Application (BLA) for...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Neutropenia Associated with Chemotherapy

Releuko patient information at Drugs.com